 |
|
|
|
September 2000 Cover
|
|
A report to pediatricians revealed that a new vaccine based on an adeno-associated virus (AAV) vector system could be useful in developing a vaccine for AIDS. Philip Johnson, developer of the vaccine, said the
AAV functions as a gene delivery system and that testing on humans could start as soon as next year. In the vaccine, the AAV vector is genetically engineered so that it transports HIV genes directly to cells. Upon entry into
the cells, the HIV genes are "turned on," proteins are generated, and the immune system responds to the attack. Johnson noted that the vaccine cannot replicate itself and cause disease, and thus cannot cause someone to
become infected with HIV.
Editor's Note: from Infectious Diseases in Children
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
